Article
Author(s):
A recent report by Heru Inc. has found that visual field (VF) results from re:Vive, its wearable testing platform, have a strong association to the ZEISS Humphrey Field Analyzer (HFA).
A recent report by Heru Inc. has found that visual field (VF) results from re:Vive, its wearable testing platform, have a strong association to the ZEISS Humphrey Field Analyzer (HFA).
The study compared the HFA to re:Vive by analyzing 47 eyes — including 21 healthy patients and 16 patients with glaucoma and neuro-ophthalmic diseases, according to a news release,
Results showed a strong correlation between both VF mean deviation and threshold values in all participants’ eyes, the company reported.
A second study was also conducted separately, bringing the total number of participants’ eyes to 81, and found similar results.
“Our patented re:Imagine™ threshold algorithm in the re:Vive platform shows a strong correlation with the Humphrey SITA Standard with excellent reproducibility, and a shorter testing time,” said Heru CEO and founder Mohamed Abou Shousha, MD, PhD.
Additional results included re:Vive performing significantly faster than the HFA SITA Standard, with a 15 percent gain in pathologic eyes and an 8 percent gain in healthy eyes, according to the company.
“Unlike legacy technology requiring patients to fixate on a static location for uncomfortable lengths of time, said Heru Chief Marketing Officer John Trefethen, “Heru’s patented ActiveTrack™ real-time gaze tracking confirms the patient’s fixation is always appropriate, improving data quality while keeping the patient engaged and focused throughout the exam.”
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.